Microdosing GLP-1s in Perimenopause: Emerging Science, Risks, and Gaps in Evidence
Microdosing GLP-1 receptor agonists like semaglutide and tirzepatide at doses significantly lower than standard prescriptions is gaining traction among clinicians treating perimenopausal women. This approach aims to address metabolic shifts caused by declining estrogen, which naturally reduces the body's own GLP-1 signaling. While low doses may improve insulin sensitivity and reduce gastrointestinal side effects, the practice remains off-label with limited rigorous scientific support. Experts emphasize that while metabolic benefits may precede weight loss, the lack of standardized guidelines and potential risks, such as muscle loss, necessitate careful, individualized medical supervision.













